45 results about "Protein biosynthesis" patented technology

This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo.

Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.

Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.

Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs.

Provided herein are methods for measuring protein biosynthesis by using ²H₂O or radioactive ³H₂O and applicable uses thereof.

Disclosed herein are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. By transfecting cells in culture with an apoptosis-inhibiting gene or vector, cells in culture can survive longer, resulting in extension of the state and yield of protein biosynthesis. Expression of the apoptosis-inhibitor within the cells, because it does not kill the cells, allows the cells, or an increased fraction thereof, to be maintained in culture for longer periods. This invention then allows for controlled, enhanced protein production of cell lines for commercial and research uses, particularly the enhanced production of growth factors, interferons, interleukins, hormones, enzymes, and monoclonal antibodies, and the like. The method preferentially involves eukaryotic cells in culture, and more advantageously mammalian cells in culture.

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

The invention relates to a method for producing a lysate used for cell-free protein biosynthesis, comprising the following steps: a) a genomic sequence in an organism, which codes for an essential translation product that reduces the yield of cell-free protein biosynthesis, is replaced by the foreign DNA located under a suitable regulatory element, said foreign DNA coding for the essential translation product that additionally contains a marker sequence; b) the organism cloned according to step a) is cultivated; c) the organisms from the culture obtained in step b) are lysed; and d) the essential translation product is eliminated by means of a separation process that is selective for the marker sequence. Also disclosed are said lysate and the use thereof.

The invention relates to a Chinese medicine composition for cooking. The composition comprises Cordyceps militaris culture medium powder and ginseng. The Cordyceps militaris culture medium powder can improve the immunity of organism, and ginseng can promote protein biosynthesis, the Cordyceps militaris culture medium powder is connected with ginseng to stabilize five internal organs, replenish Qi and blood so as to harmonize the heart-fire and benefit the digestive function of spleen.

The MAOI hydrazide substrate is targeted by protease cleavage in cells that host cancer, viral infections, or other malignant diseases because the hydrazide substrate (R′NHNHCOR″) simulates the peptide bonds (R′NHCOR″) that are innately targeted by protease cleavage. However cleavage of the hydrazide substrate forms a hydrazine radical which bonds to the protease enzyme to provide an irreversible substrate action that shuts down cell protein biosynthesis thereafter. Such process renders the malignant host cells sterile, static, and doomed to apoptosis where a disease free replacements cell can then be provided. The MAOI hydrazide drug also provides a new antibiotic purpose by rendering cells innate to infectious organisms sterile, static, and therefore harmless.

Disclosed is a pharmaceutical composition containing an extract of Schisandrae Fructus for preventing and treating metabolic bone diseases, oxidative stress-induced diseases and inflammatory diseases.

The composition of the present invention contains the extract of Schisandrae Fructus showing increasing action on bone mineralization and protein biosynthesis, antioxidant action and anti-inflammation and analgesic actions, and can be used as a direct therapeutic agent or a therapeutic aide for metabolic bone diseases, oxidative stress-induced diseases and inflammatory diseases.

A therapeutic agent of the present invention is of a natural medicament containing the extract of Schisandrae Fructus, that is, a kind of medicinal plants, and shows the above described actions without any adverse side effect shown in conventional synthetic medicaments, thereby preferably replacing the conventional synthetic medicaments.

The invention relates to a novel virus double-fluorescence labeling method based on nucleic acid and protein biosynthesis, and belongs to the field of chemistry and biomedicine. The method comprises specific steps as follows: a methionine analogue methionine azide and a deoxythymidine analogue ethylene deoxyuridine are synthesized; viruses are added to host cells for infection, methionine azide and ethylene deoxyuridine are added respectively, vinyl derivation of viral nucleic acid and azido derivation of protein are realized with biosynthesis processes of nucleic acid and protein; double-fluorescence labeling of viral nucleic acid and protein is naturally realized through two biological orthogonal reactions including a Diels-Alder reaction of tetrazine-oefin and a copper-free catalytic click chemical reaction of azido-cyclooctyne. The labeling method is simple, convenient and reliable, can be applied to all DNA (deoxyribonucleic acid) viruses including single-stranded DNA viruses, double-stranded DNA viruses, enveloped viruses and non-enveloped viruses, and is a universal virus fluorescence labeling method on an absolute basis.

The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.

The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts.

The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selectively prevent gene transcription and expression in a sequence-specific manner. In particular, this invention is directed to the selective inhibition of protein biosynthesis via antisense strategy using oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length. Particularly this invention relates to the use of antisense oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length, to hybridize to complementary RNA such as cellular messenger RNA, viral RNA, etc. More particularly this invention relates to the use of antisense oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length, to hybridize to and induce cleavage of (via RNaseH activation) the complementary RNA.

The invention having functional vertical disposable reaction systems having a vertically mounted semipermeable membrane for sample preparation, chemical reactions, dialysis, enzymatic/microbiological fermentation, multistage processes, in vitro protein biosynthesis on a laboratory scale, formed from a base body and an exchangeable lid having different functions. For exchange across the membrane, the system is placed vertically into an outer volume consisting of gas, liquid or solid constituents. The system consists of a dimensionally stable base body and a liquid-tight lid having a functional support going toward the base of the base body, the dimensionally stable base body forming at least one noncapillary reaction space as inner volume with at least one semipermeable membrane as lateral wall. The high flexibility in use results from the combination of variants of the base bodies with different lid variants for different areas of use. The base bodies having different membranes and volumes can be coupled with lids having different feeding openings, contacts, sensor supports, gas supply means, circulation means, etc. This yields, in the case of m different base bodies and n different lid variants, m×n combinations having different properties.